Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder

Sulma I. Mohammed, Deborah W. Knapp, David G. Bostwick, Richard S. Foster, Kanwar Nasir M. Khan, Jaime L. Masferrer, Bryan M. Woerner, Paul W. Snyder, Alane T. Koki

Research output: Contribution to journalArticle

267 Scopus citations

Abstract

Cyclooxygenase (COX)-inhibiting drugs have antitumor activity in canine and rodent models of urinary bladder cancer. Two isoenzymes of COX have been identified, COX-1 and COX-2. The purpose of this study was to characterize COX-1 and COX-2 expression in human invasive transitional cell carcinoma of the urinary bladder by immunohistochemistry and Western blot analysis. COX-2 was not expressed in normal urinary bladder samples but was detected in 25 of 29 (86%) invasive transitional cell carcinomas of the urinary bladder and in 6 of 8 (75%) cases of carcinoma in situ. These results indicate that COX-2 may play a role in bladder cancer in humans and support further study of COX- 2 inhibitors as potential antitumor agents in human bladder cancer.

Original languageEnglish (US)
Pages (from-to)5647-5650
Number of pages4
JournalCancer Research
Volume59
Issue number22
StatePublished - Nov 15 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder'. Together they form a unique fingerprint.

  • Cite this

    Mohammed, S. I., Knapp, D. W., Bostwick, D. G., Foster, R. S., Khan, K. N. M., Masferrer, J. L., Woerner, B. M., Snyder, P. W., & Koki, A. T. (1999). Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Research, 59(22), 5647-5650.